EBMT-EHA CAR-T 2019 | Bringing CAR T-cell therapy to the mainstream
Ulrich Jäger
• 15 Feb 2019
Ulrich Jäger, MD, from the Medical University of Vienna, Vienna, Austria, discusses how CAR T-cell treatment was developed predominantly in academic institutions, but that industry has been vital in the treatments implementation within the clinical setting. Speaking at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and European Hematology Association (EHA), Prof. Jäger goes on to reflect upon what’s needed in the future, explaining how CAR-T needs to be more cost-effective to ensure it’s available to those who need it.
